doi:10.1080/14656566.2024.2356254
The redox potential of compounds reducing an oxidant must be lower than that of the oxidant
In contrast, GLP-1 agonism for the treatment of type 1 diabetes remains unproven, with initial results from smaller investigator-conceived studies being inconclusive
For instance, SIRT5 increases the activity of GAPDH by demalonylation, thereby controlling the energetic flux through glycolysis
Kost is senior vice president and chief compliance officer of Wellstar, Mullins is executive president of ambulatory and business development, and Teer is senior vice president and president of the Wellstar Foundation
However, subgroup analysis showed a non-significant trend in the effect on the incidence of fatal or nonfatal stroke or transient ischaemic attack during a follow-up of 3.8 years [19]